Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. - Wikidata - wikimedia - TriplyDB

Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.

Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.

http://www.wikidata.org/entity/Q37203867

about

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.

P2860

Q46323872-A73C86CB-1D60-4769-B7E0-DDCE20B1A17E

P2860

Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.

http://www.wikidata.org/entity/Q37203867

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@en

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@nl

type

label

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@en

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@nl

prefLabel

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@en

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@nl

P1433

Q37203867-68B67308-A46C-4681-B4D9-76E7B243274B

P1476

Q37203867-F259B386-F9D4-4D38-B572-E23E14C180B5

P2093

Q37203867-21F5CCDA-A3F9-4294-9E6D-0EA1306EC1ED

Q37203867-22B8C61C-5E6E-4634-ADAB-5D7DD5C4EBA0

Q37203867-268B2A0A-8024-4779-954F-6F3D17A9A2EA

Q37203867-3724208E-7607-414A-B531-11866DCC0CC6

Q37203867-397AFDF1-7944-49F6-8BA4-8E13CFCA2718

Q37203867-4530903A-A201-4D5E-A965-E1B4284D8E73

Q37203867-57D0AD93-AD69-48FA-93E3-F00FAD534973

Q37203867-755A286B-0ABF-4FE7-A8F6-D16A79D1EE3A

Q37203867-C5318C49-3DE3-479B-9BF9-CA9E41AA64A0

Q37203867-D13FA3EA-2AF9-445F-9C66-751CBC6C49F7

P2860

Q37203867-0D7152AC-3C3A-4145-AF89-DE4A8F3D9EA4

Q37203867-0E755E9A-D09C-4488-861F-DAC654D5D980

Q37203867-195DCB2B-E090-4DB7-9496-EA230B20324C

Q37203867-1DE20B6C-4A44-4E11-AC04-9C5307ACB55B

Q37203867-231EBC8A-03D7-47DA-BD92-DDD5B1BB8F19

Q37203867-2D85887E-9FB8-43AC-9951-1A437DA3CCCA

Q37203867-34B8EF8B-1286-4374-B2EE-5118D18C1BE8

Q37203867-3C3C9DE4-F9F7-415E-8F0C-C519B5387CCE

Q37203867-4670933B-12FC-48A1-99F8-FFB2026B4B03

Q37203867-52304E65-14FF-4BD1-9D69-49EB8CFC30F1

P304

Q37203867-681D3852-8D5B-4304-9745-30A77289605F

P31

Q37203867-CD0A5233-CF4D-43A0-946F-856A9C989C2A

P356

Q37203867-D37F2B42-D87C-43D2-914D-B093EDCC8434

P407

Q37203867-584B5FA2-7CF0-41B0-A858-A9A91C148D4C

P433

Q37203867-EA79A9E2-4FB2-49BB-8A88-1EBCE4910AC3

P478

Q37203867-F3739065-59D4-4B65-A88D-064CE5E68CC6

P577

Q37203867-37EB79FA-1E48-47E7-81AB-8F2BA37CDC74

P698

Q37203867-2316029F-44FF-4D05-82BD-87C8B6BE8019

P932

Q37203867-00C97587-BDF3-4665-A9B0-E693B6F77BDC

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population Pharmacokinetics of ...... ect of Dose Reporting Methods.

@en

P2093

Ayyappa Chaturvedula

http://www.w3.org/2001/XMLSchema#string

Connie L Celum

http://www.w3.org/2001/XMLSchema#string

Craig W Hendrix

http://www.w3.org/2001/XMLSchema#string

David Bangsberg

http://www.w3.org/2001/XMLSchema#string

Jared M Baeten

http://www.w3.org/2001/XMLSchema#string

Jessica E Haberer

http://www.w3.org/2001/XMLSchema#string

Mark E Sale

http://www.w3.org/2001/XMLSchema#string

Michael J Fossler

http://www.w3.org/2001/XMLSchema#string

Vineet Goti

http://www.w3.org/2001/XMLSchema#string

Yanhui Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa

Preexposure prophylaxis for HIV infection among African women

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

P304

5379-5386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00559-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27353269

http://www.w3.org/2001/XMLSchema#string

P932

4997873

http://www.w3.org/2001/XMLSchema#string